Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Caroline Baldwyn

Physician Assistant, Medical Madison, MS Physician Assistant

NPI 1760075535 CMS profile 11158241

1607 Doctors Dr, Madison, MS 39110

Open in the dashboard

General payments

$8,680

463 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Caroline Baldwyn of Madison, MS is reported in the CMS Open Payments database as having received $8,680 across 463 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,577 101
2024 General $1,821 95
2023 General $1,636 83
2022 General $1,790 97
2021 General $1,856 87

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Caroline Baldwyn
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Caroline Baldwyn were reported at $1,577. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Caroline Baldwyn Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,856 $156 $41–$563 $132
2022 $1,790 $185 $55–$649 $149
2023 $1,636 $199 $58–$717 $160
2024 $1,821 $206 $62–$740 $164
2025 $1,577 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $3,458 174 payments
  2. Amgen Inc. $2,040 113 payments
  3. Novartis Pharmaceuticals Corporation $622 55 payments
  4. Lilly USA, LLC $315 16 payments
  5. Mallinckrodt Hospital Products Inc. $311 11 payments
  6. Janssen Biotech, Inc. $289 16 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $248 15 payments
  8. Inari Medical, Inc. $226 3 payments
  9. Pfizer Inc. $213 10 payments
  10. GlaxoSmithKline, LLC. $212 9 payments
  11. Other $746 41 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,680 463 payments
Products named General payments · program years 2021–2025
  1. RINVOQ $2,869 143 payments
  2. Otezla $1,000 54 payments
  3. Enbrel Inflammation $899 51 payments
  4. Enbrel Inflammation $462 26 payments
  5. COSENTYX $448 47 payments
  6. SKYRIZI $431 20 payments
  7. TALTZ $315 16 payments
  8. ACTHAR $311 11 payments
  9. OFEV $297 18 payments
  10. TREMFYA $289 16 payments
  11. Other $3,244 158 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

513

Median for Physician Assistant: 241

Drug cost

$13,302

Median for Physician Assistant: $4,110

Branded share of claims

15.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydroxychloroquine Sulfate Generic 121 $4,643
Methotrexate Methotrexate Sodium Brand 78 $2,497
Azathioprine Generic 20 $1,600
Celecoxib Generic 52 $1,035
Leflunomide Generic 17 $922
Tizanidine Hcl Generic 37 $614
Gabapentin Generic 35 $524
Duloxetine Hcl Generic 18 $462
Sulfasalazine Generic 18 $408
Cyclobenzaprine Hcl Generic 24 $228

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $489
$489 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $153
$153 — —
Enbrel
  • Amgen Inc. $150
$150 — —
SKYRIZI
  • AbbVie, Inc. $130
$130 — —
Otezla
  • Amgen Inc. $103
$103 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

463 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record